1. Harbeck N, Penault-Llorca F, Cortes J, et al. Breast cancer. Nat Rev Dis Primer 2019; 5: 1-31.
2.
Koboldt DC, Fulton RS, McLellan MD, et al. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
3.
Sharma P, Klemp JR, Kimler BF, et al. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing. Breast Cancer Res Treat 2014; 145: 707-714.
4.
Lord CJ, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic. Science 2017; 355: 1152-1158.
5.
Wong-Brown MW, Meldrum CJ, Carpenter JE, et al. Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer. Breast Cancer Res Treat 2015; 150: 71-80.
6.
Stevens KN, Vachon CM, Couch FJ. Genetic Susceptibility to Triple-Negative Breast Cancer. Cancer Res 2013; 73: 2025-2030.
7.
Xu Y, Diao L, Chen Y, et al. Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy. Ann Oncol 2013; 24: 1498-1505.
8.
Glodzik D, Bosch A, Hartman J, et al. Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers. Nat Commun 2020; 11: 3747.
9.
Marquard AM, Eklund AC, Joshi T, et al. Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs. Biomark Res 2015; 3: 9.
10.
Miller RE, Leary A, Scott CL, et al. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Ann Oncol 2020; 31: 1606-1622.
11.
Vanderstichele A, Busschaert P, Olbrecht S, et al. Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer. Eur J Cancer 2017; 86: 5-14.
12.
Chopra N, Tovey H, Pearson A, et al. Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer. Nat Commun 2020; 11: 2662.
13.
Staaf J, Glodzik D, Bosch A, et al. Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study. Nat Med 2019; 25: 1526-1533.
14.
Shah SP, Roth A, Goya R, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Natur 2012; 486: 395-399.
15.
Liu Z, Jiang Z, Gao Y, et al. TP53 Mutations Promote Immunogenic Activity in Breast Cancer. J Oncol Hindawi 2019; 2019: e5952836.
16.
Na B, Yu X, Withers T, et al. Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation. NPJ Breast Cancer 2019; 5: 14.
17.
Li J, Zhang X, Zhang Z, et al. Association of p53 expression with poor prognosis in patients with triple-negative breast invasive ductal carcinoma. Medicine (Baltimore) 2019; 98: e15449.
18.
Pascual J, Turner NC. Targeting the PI3-kinase pathway in triple-negative breast cancer. Ann Oncol 2019; 30: 1051-1060.
19.
Martínez-Sáez O, Chic N, Pascual T, et al. Frequency and spectrum of PIK3CA somatic mutations in breast cancer. Breast Cancer Res BCR. 2020; 22: 45.
20.
Kumar S, Bal A, Das A, et al. Spectrum of PIK3CA/AKT mutations across molecular subtypes of triple-negative breast cancer. Breast Cancer Res Treat. 2021; 187: 625-633.
21.
Barroso-Sousa R, Keenan TE, Pernas S, et al. Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer. Clin Cancer Res 2020; 26: 2565-2572.
22.
Hu H, Zhu J, Zhong Y, et al. PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway. Ann Transl Med 2021; 9: 410.
23.
Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 2018; 15: 731-747.
24.
Solomon JP, Linkov I, Rosado A, et al. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol Off J U S Can Acad Pathol Inc 2020; 33: 38-46.
25.
Krings G, Joseph NM, Bean GR, et al. Genomic profiling of breast secretory carcinomas reveals distinct genetics from other breast cancers and similarity to mammary analog secretory carcinomas. Mod Pathol Off J U S Can Acad Pathol Inc 2017; 30: 1086-1099.
26.
Osako T, Takeuchi K, Horii R, et al. Secretory carcinoma of the breast and its histopathological mimics: value of markers for differential diagnosis. Histopathology 2013; 63: 509-519.
27.
Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children. N Engl J Med [Internet]. Massachusetts Medical Society; 2018
28.
Drilon A. TRK inhibitors in TRK fusion-positive cancers. Ann Oncol 2019; 30: viii23-30.
29.
Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov 2019; 9: 176-198.
30.
Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121: 2750-2767.
31.
Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA. New strategies for triple negative breast cancer – deciphering the heterogeneity. Clin Cancer Res Off J Am Assoc Cancer Res 2014; 20: 782-790.
32.
Ryś J, Kruczak A. Triple- negative breast cancer (triple - negative breast cancer) - homogeneous or heterogeneous group of cancers ?. Pol J Pathol 2014; 65: S53-61.
33.
Masuda H, Baggerly KA, Wang Y, et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res Off J Am Assoc Cancer Res 2013; 19: 10.1158/1078-0432.CCR-13–0799.
34.
Lehmann BD, Jovanović B, Chen X, et al. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS One 2016; 11: e0157368.
35.
Echavarria I, López-Tarruella S, Picornell A, et al. Pathological response in a triple-negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann’s refined classification. Clin Cancer Res Off J Am Assoc Cancer Res 2018; 24: 1845-1852.
36.
Burstein MD, Tsimelzon A, Poage GM, et al. Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-negative Breast Cancer. Clin Cancer Res Off J Am Assoc Cancer Res 2015; 21: 1688-1698.
37.
Bareche Y, Buisseret L, Gruosso T, et al. Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach. JNCI J Natl Cancer Inst 2019; 112: 708-719.
38.
Domagala P, Hybiak J, Cybulski C, Lubinski J. BRCA1/2-negative hereditary triple-negative breast cancers exhibit BRCAness. Int J Cancer 2017; 140: 1545-1550.
39.
Jin J, Zhang W, Ji W, et al. Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy. Cancer Biol Ther 2017; 18: 369-378.
40.
Marra A, Trapani D, Viale G, et al. Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. NPJ Breast Cancer 2020; 6: 54.
41.
Zhao S, Zuo WJ, Shao ZM, Jiang YZ. Molecular subtypes and precision treatment of triple-negative breast cancer. Ann Transl Med 2020; 8: 499.
